Filipovic1 and Ivana Djuric-Filipovic2
Unit, Emergency Institute, Belgarde, Republic of Serbia, 2Immunology,
Faculty of Medical Science Kragujevac, Kragujevac, Republic of Serbia
The morbidity associated
with mild to moderate asthma is very high in developing countries. The
aim of this study was to describe the role of allergen immunotherapy in
prevention of asthma exacerbation and hospitalization in children with
mild to moderate asthma.
59 asthmatic children were included in the study. 34 patients were
received AIT drops plus standard pharmacotherapy while 29 children
received only standard pharmacotherapy according to the GINA guideline.
Efficacy was evaluated using rescue medication score, oral
corticosteroids score and asthma symptoms score (chest tightness,
shortness of breath, cough and wheezing) during the two years. We
analysed results at the baseline, after the one and after two years of
Read More :
isn?t everything (for infant immunity)
Asthma score was decreased during the first year of treatment, with the
tendency of further decrease in the second year of follow up period.
The most important effects of SLIT were observed for the symptom of
wheezing and night cough (X2=56,790; p<0,001, X2=56,142;
p<0,001) only in the experimental group. Additional significant
improvements were also observed for rescue medication (p<0,001)
and oral corticosteroids (p<0,001). The rate of exacerbation in
experimental group was significant lower in comparison with that rate
in control group. The same improvement was found also in the
It has been already known that allergen immunotherapy reduce asthma and
drug scores. In our study we found that AIT has a positive impact on
asthma hospitalization and exacerbation rate in children with mild to
moderate asthma. AIT can prevent development of severe asthma in
children with mild to moderate asthma.